Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303

1.

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.

Am J Gastroenterol. 2013 Sep;108(9):1458-63. doi: 10.1038/ajg.2013.219. Epub 2013 Jul 23.

PMID:
23877348
2.
3.

Durability of rifaximin response in hepatic encephalopathy.

Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N.

J Clin Gastroenterol. 2012 Feb;46(2):168-71. doi: 10.1097/MCG.0b013e318231faae.

PMID:
22011586
4.

Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy.

Sharma BC, Singh J, Srivastava S, Sangam A, Mantri AK, Trehanpati N, Sarin SK.

J Gastroenterol Hepatol. 2017 Jun;32(6):1234-1239. doi: 10.1111/jgh.13666.

PMID:
27885712
5.

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J.

Transplant Proc. 2006 Dec;38(10):3552-5.

PMID:
17175328
6.

RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.

Schulz C, Schütte K, Kropf S, Schmitt FC, Vasapolli R, Kliegis LM, Riegger A, Malfertheiner P.

Trials. 2016 Feb 29;17(1):111. doi: 10.1186/s13063-016-1205-8.

7.

Rifaximin treatment in hepatic encephalopathy.

Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP.

N Engl J Med. 2010 Mar 25;362(12):1071-81. doi: 10.1056/NEJMoa0907893.

8.

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.

Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP.

Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug 17.

9.

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.

Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM.

Yonsei Med J. 2005 Jun 30;46(3):399-407.

10.

Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.

Courson A, Jones GM, Twilla JD.

J Pharm Pract. 2016 Jun;29(3):212-7. doi: 10.1177/0897190014566312. Epub 2015 Jan 13.

PMID:
25586470
11.

Combination therapy for the treatment and prevention of hepatic encephalopathy.

Mohammad RA, Regal RE, Alaniz C.

Ann Pharmacother. 2012 Nov;46(11):1559-63. doi: 10.1345/aph.1R146. Epub 2012 Oct 23. Review.

PMID:
23092866
12.

Update on management of patients with overt hepatic encephalopathy.

Chacko KR, Sigal SH.

Hosp Pract (1995). 2013 Aug;41(3):48-59. doi: 10.3810/hp.2013.08.1068. Review.

PMID:
23948621
13.
14.

Rifaximin for the treatment of hepatic encephalopathy.

Mantry PS, Munsaf S.

Transplant Proc. 2010 Dec;42(10):4543-7. doi: 10.1016/j.transproceed.2010.09.173.

PMID:
21168733
15.

Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.

Ahire K, Sonawale A.

J Assoc Physicians India. 2017 Aug;65(8):42-46.

PMID:
28799305
16.

Rifaximin for treatment of hepatic encephalopathy.

Maclayton DO, Eaton-Maxwell A.

Ann Pharmacother. 2009 Jan;43(1):77-84. doi: 10.1345/aph.1K436. Epub 2008 Dec 17. Review.

PMID:
19092143
17.

Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.

Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S.

Clin Gastroenterol Hepatol. 2014 Jun;12(6):1003-8.e1. doi: 10.1016/j.cgh.2013.11.006. Epub 2013 Nov 15.

PMID:
24246768
18.

 Minimal hepatic encephalopathy in cirrhosis- how long to treat?

Goyal O, Sidhu SS, Kishore H.

Ann Hepatol. 2017 Jan-Feb 2017;16(1):115-122. doi: 10.5604/16652681.1226822.

19.

An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.

Sharma P, Sharma BC, Puri V, Sarin SK.

Eur J Gastroenterol Hepatol. 2008 Jun;20(6):506-11. doi: 10.1097/MEG.0b013e3282f3e6f5.

PMID:
18467909
20.

Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.

Sharma P, Sharma BC, Agrawal A, Sarin SK.

J Gastroenterol Hepatol. 2012 Aug;27(8):1329-35. doi: 10.1111/j.1440-1746.2012.07186.x.

PMID:
22606978

Supplemental Content

Support Center